These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 10343053)

  • 1. Section 8(c) of the proposed Restatement (Third) of Torts: is it really what the doctor ordered?
    Winchester JD
    Cornell Law Rev; 1997 Mar; 82(3):644-93. PubMed ID: 10343053
    [No Abstract]   [Full Text] [Related]  

  • 2. The new Restatement (Third) of Torts--shelter from the product liability storm for pharmaceutical companies and medical device manufacturers?
    Wagner MJ; Peterson LL
    Food Drug Law J; 1998; 53(2):225-42. PubMed ID: 10346683
    [No Abstract]   [Full Text] [Related]  

  • 3. Enterprise liability for bad outcomes from drug therapy: the doctor, the hospital, the pharmacy, and the drug firm.
    Furrow BR
    Spec Law Dig Health Care Law; 1998 Apr; (229):9-69. PubMed ID: 10178162
    [No Abstract]   [Full Text] [Related]  

  • 4. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 5. Ejecting the FDA from the courtroom.
    Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
    [No Abstract]   [Full Text] [Related]  

  • 6. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 7. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 9. Forces reshaping the performance and contribution of the U.S. medical device industry.
    Benson JS
    Food Drug Law J; 1996; 51(2):331-6. PubMed ID: 11822326
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 11. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 12. Manufacturers' liability for drugs and medical devices under the Restatement (Third) of Torts: Products Liability.
    Dreier WA
    Seton Hall Law Rev; 1999; 30(1):258-64. PubMed ID: 10848105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 14. US bill to shield drug companies from product liability.
    Lenzer J
    BMJ; 2005 Jan; 330(7482):62. PubMed ID: 15637367
    [No Abstract]   [Full Text] [Related]  

  • 15. The Supreme Court rules on medical device liability--or does it?
    Richards EP
    IEEE Eng Med Biol Mag; 1997; 16(1):87-8, 90. PubMed ID: 9058587
    [No Abstract]   [Full Text] [Related]  

  • 16. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Medical Device Safety Act of 2009.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2009 Apr; 360(15):1550-1. PubMed ID: 19297562
    [No Abstract]   [Full Text] [Related]  

  • 18. The "tone at the top": can it mitigate C-suite personal liability?
    Page GV; Waring MA; Kaiser GR; Cornish K
    Food Drug Law J; 2008; 63(3):723-34. PubMed ID: 19031671
    [No Abstract]   [Full Text] [Related]  

  • 19. New regulation requires reporting of significant medical device problems.
    FDA Drug Bull; 1984 Dec; 14(3):26. PubMed ID: 6526175
    [No Abstract]   [Full Text] [Related]  

  • 20. Leave regulation to the FDA.
    Hughes OC
    Science; 2008 Jul; 321(5888):490. PubMed ID: 18653865
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.